纽约的一家律师事务所调查MoonLake Immunotherathertics 在试验失败导致股票下跌80%之后,据称投资者的误报导致的投资者误报。 A NY law firm investigates MoonLake Immunotherapeutics over alleged investor misrepresentation after trial failures caused stock to drop 80%.

一家纽约证券律师事务所(MLTX)已就潜在的投资者错误陈述启动了对MoonLake Immunotheretics(MLTX)的调查,因为该公司宣布其晚期对Snelokimab的试验之一未能达到其主要终点,而另一家则只显示出微小、低于预期的结果。 A New York securities law firm has launched an investigation into MoonLake Immunotherapeutics (MLTX) over potential investor misrepresentation following the company’s announcement that one of its late-stage trials for sonelokimab failed to meet its primary endpoint, while the other showed only modest, below-expectation results. 这一消息导致该股暴跌超过 80%，引发了人们对该药物批准和商业前景的担忧。 The news caused the stock to plummet over 80%, raising concerns about the drug’s approval and commercial prospects. 该公司正在审查公司在释放前是否提供了误导性信息,遭受损失的投资者是否有资格在没有预付费用的情况下参加潜在的集体诉讼诉讼。 The firm is examining whether the company provided misleading information prior to the release, and investors who suffered losses may be eligible to join a potential class action lawsuit with no upfront costs.